5.0.0.0 Ref­er­ences

  1. Stellef­son M, Dip­nar­ine K, Stop­ka C. The Chron­ic Care Model and di­a­betes man­age­ment in US pri­ma­ry care set­tings: a sys­tematic re­view. Prev Chron­ic Dis 2013;10:E26
  2. Cole­man K, Austin BT, Brach C, Wag­n­er EH. Ev­i­dence on the Chron­ic Care Model in the new mil­len­ni­um. Health Aff (Mill­wood) 2009;28:75–85
  3. Gab­bay RA, Bailit MH, Mauger DT, Wag­n­er EH, Simine­r­io L. Mul­ti­pay­er pa­tient-‍cen­tered med­i­cal home im­ple­men­ta­tion guid­ed by the chron­ic care model. Jt Comm J Qual Pa­tient Saf 2011;37: 265–273
  4. UK Prospec­tive Di­a­betes Study (UKPDS) Group. In­ten­sive blood-‍glu­cose con­trol with sulpho­ny­lureas or in­sulin com­pared with con­ven­tion­al treat­ment and risk of com­pli­ca­tions in pa­tients with type 2 di­a­betes (UKPDS 33). Lancet 1998;352:837–853
  5. Nathan DM, Genuth S, Lachin J, et al.; Di­a­betes Con­trol and Com­pli­ca­tions Trial Re­search Group. The ef­fect of in­ten­sive treat­ment of di­a­betes on the de­vel­opment and pro­gres­sion of longterm com­pli­ca­tions in in­sulin-dependent di­a­betes mel­li­tus. N Engl J Med 1993;329:977–986
  6. Lachin JM, Genuth S, Nathan DM, Zin­man B, Rut­ledge BN; DCCT/EDIC Re­search Group. Ef­fect of glycemic ex­po­sure on the risk of microvas­cu­lar com­pli­ca­tions in the Di­a­betes Con­trol and Com­pli­ca­tions Tri­al­drevis­it­ed. Di­a­betes 2008; 57:995–1001
  7. White NH, Cleary PA, Dahms W, Gold­stein D, Mal­one J, Tam­bor­lane WV; Di­a­betes Con­trol and Com­pli­ca­tions Trial (DCCT)/‍Epi­demi­ology of Di­a­betes In­ter­ven­tions and Com­pli­ca­tions (EDIC) Re­search Group. Beneficial ef­fects of in­ten­sive ther­a­py of di­a­betes dur­ing ado­les­cence: out­comes after the con­clu­sion of the Di­a­betes Con­trol and Com­pli­ca­tions Trial (DCCT). J Pe­di­atr 2001;139:804–812
  8. An­der­son RM, Fun­nell MM. Com­pli­ance and ad­her­ence are dysfunc­tional con­cepts in di­a­betes care. Di­a­betes Educ 2000;26:597–604
  9. Sarkar U, Fish­er L, Schillinger D. Is self-‍efficacy as­so­ci­at­ed with di­a­betes self-‍man­age­ment across race/‍ethnicity and health lit­er­a­cy? Di­a­betes Care 2006;29:823–829
  10. King DK, Glas­gow RE, Toobert DJ, et al. Self­efficacy, prob­lem solv­ing, and so­cial-environmen­tal sup­port are as­so­ci­at­ed with di­a­betes selfman­age­ment be­hav­iors. Di­a­betes Care 2010; 33:751–753
  11. Nouwen A, Urquhart Law G, Hus­sain S, Mc­Gov­ern S, Napi­er H. Com­par­i­son of the role of self-‍efficacy and ill­ness repre­sentations in re­la­tion to di­etary self-‍care and di­a­betes dis­tress in ado­les­cents with type 1 di­a­betes. Psy­chol Health 2009;24:1071–1084
  12. Beck­er­le CM, Lavin MA. As­so­ci­a­tion of self-‍efficacy and self-‍care with glycemic con­trol in di­a­betes. Di­a­betes Spec­tr 2013;26:172–178
  13. Ian­not­ti RJ, Schnei­der S, Nansel TR, et al. Self-‍efficacy, out­come ex­pec­ta­tions, and di­a­betes self-‍man­age­ment in ado­les­cents with type 1 di­a­betes. J Dev Behav Pe­di­atr 2006;27:98–105
  14. Dick­in­son JK, Guz­man SJ, Maryniuk MD, et al. The use of lan­guage in di­a­betes care and ed­u­ca­tion. Di­a­betes Care 2017;40:1790–1799
  15. Lee SWH, Ng KY, Chin WK. The im­pact of sleep amount and sleep qual­i­ty on glycemic con­trol in type 2 di­a­betes: a sys­tematic re­view and meta-‍anal­y­sis. Sleep Med Rev 2017:31:91– 101
  16. Robin­son CL, Romero JR, Kempe A, Pel­le­gri­ni C; Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices (ACIP) Child/‍Adolescent Im­mu­niza­tion Work Group. Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices rec­om­mend­ed im­mu­niza­tion sched­ule for chil­dren and ado­les­cents aged 18 years or younger­dUnit­ed States, 2017. MMWR Morb Mor­tal Wkly Rep 2017; 66:134–135
  17. Kim DK, Riley LE, Har­ri­man KH, Hunter P, Bridges CB. Ad­vi­so­ry Com­mit­tee on Im­mu­niza­tion Prac­tices rec­om­mend­ed im­mu­niza­tion sched­ule for adults aged 19 years or old­erd Unit­ed States, 2017. MMWR Morb Mor­tal Wkly Rep 2017;66:136–138
  18. Goei­jen­bier M, van Sloten TT, Slobbe L, et al. Benefits of flu vac­ci­na­tion for per­sons with di­a­betes mel­li­tus: a re­view. Vac­cine 2017;35:5095– 5101
  19. Smith SA, Poland GA. Use of influenza and pneu­mo­coc­cal vac­cines in peo­ple with di­a­betes. Di­a­betes Care 2000;23:95–108
  20. Selvin E, Core­sh J, Bran­cati FL. The bur­den and treat­ment of di­a­betes in el­der­ly in­di­vid­u­als in the U.S. Di­a­betes Care 2006;29:2415– 2419
  21. Grant RW, Ash­burn­er JM, Hong CS, Chang Y, Barry MJ, Atlas SJ. Defining pa­tient com­plex­i­ty from the pri­ma­ry care physi­cian’s perspec­tive: a co­hort study [pub­lished cor­rec­tion ap­pears in Ann In­tern Med 2012;157:152]. Ann In­tern Med 2011;155:797–804
  22. Tinet­ti ME, Fried TR, Boyd CM. De­sign­ing health care for the most com­mon chron­ic conditiondmultimor­bid­i­ty. JAMA 2012;307:2493– 2494
  23. Su­dore RL, Karter AJ, Huang ES, et al. Symp­tom bur­den of adults with type 2 di­a­betes across the dis­ease course: Di­a­betes & Aging Study. J Gen In­tern Med 2012;27:1674–1681
  24. Borgnakke WS, Ylo¨stalo PV, Tay­lor GW, Genco RJ. Ef­fect of pe­ri­odon­tal dis­ease on di­a­betes: sys­tematic re­view of epi­demi­o­log­ic ob­ser­va­tion­al ev­i­dence. J Pe­ri­odon­tol 2013;84 (Suppl.):S135–S152
  25. Tri­o­lo TM, Arm­strong TK, Mc­Fann K, et al. Ad­di­tion­al au­toim­mune dis­ease found in 33% of pa­tients at type 1 di­a­betes onset. Di­a­betes Care 2011;34:1211–1213
  26. Hugh­es JW, Rid­dlesworth TD, DiMeglio LA, Miller KM, Rick­els MR, McGill JB. Au­toim­mune dis­eases in chil­dren and adults with type 1 di­a­betes from the T1D Ex­change Clin­ic Reg­istry. J Clin En­docrinol Metab 2016;101:4931– 4937
  27. Ka­haly GJ, Hansen MP. Type 1 di­a­betes as­so­ci­at­ed au­toim­mu­ni­ty. Au­toim­mun Rev 2016;15:644–648
  28. Eisen­barth GS, Got­tlieb PA. Au­toim­mune polyen­docrine syn­dromes. N Engl J Med 2004; 350:2068–2079
  29. Suh S, Kim K-W. Di­a­betes and can­cer: is di­a­betes causal­ly re­lat­ed to can­cer? Di­a­betes Metab J 2011;35:193–198
  30. Gio­van­nuc­ci E, Har­lan DM, Archer MC, et al. Di­a­betes and can­cer: a con­sen­sus re­port. CA Can­cer J Clin 2010;60:207–221
  31. Ag­gar­w­al G, Ka­ma­da P, Chari ST. Preva­lence of di­a­betes mel­li­tus in pan­cre­at­ic can­cer com­pared to com­mon can­cers. Pan­creas 2013;42: 198–201
  32. Cukier­man T, Ger­stein HC, Williamson JD. Cog­ni­tive de­cline and de­men­tia in di­a­betesd sys­tematic overview of prospec­tive ob­ser­va­tion­al stud­ies. Di­a­betolo­gia 2005;48:2460–2469
  33. Bies­sels GJ, Staeken­borg S, Brun­ner E, Brayne C, Schel­tens P. Risk of de­men­tia in di­a­betes mel­li­tus: a sys­tematic re­view. Lancet Neu­rol 2006;5:64–74
  34. Gu­dala K, Bansal D, Schi­fano F, Bhansali A. Di­a­betes mel­li­tus and risk of de­men­tia: a meta­anal­y­sis of prospec­tive ob­ser­va­tion­al stud­ies. J Di­a­betes In­ves­tig 2013;4:640–650
  35. Ohara T, Doi Y, Ni­nomiya T, et al. Glu­cose tol­er­ance sta­tus and risk of de­men­tia in the com­mu­ni­ty: the Hisaya­ma study. Neu­rology 2011;77:1126–1134
  36. Cukier­man-‍Yaffe T, Ger­stein HC, Williamson JD, et al.; Ac­tion to Con­trol Car­dio­vas­cu­lar Risk in Di­a­betes-Memory in Di­a­betes (AC­CORD-‍MIND) In­ves­tigators. Re­la­tion­ship be­tween base­line glycemic con­trol and cog­ni­tive func­tion in in­di­vid­u­als with type 2 di­a­betes and other car­dio­vas­cu­lar risk fac­tors: the Ac­tion to Con­trol Car­dio­vas­cu­lar Risk in Di­a­betes-Memory in Di­a­betes (AC­CORD-‍MIND) trial. Di­a­betes Care 2009;32:221–226
  37. Launer LJ, Miller ME, Williamson JD, et al.; AC­CORD MIND In­ves­tigators. Ef­fects of in­ten­sive glu­cose low­er­ing on brain struc­ture and func­tion in peo­ple with type 2 di­a­betes (AC­CORD MIND): a ran­domised open-‍label sub­study. Lancet Neu­rol 2011;10:969–977
  38. Whit­mer RA, Karter AJ, Yaffe K, Que­sen­ber­ry CP Jr, Selby JV. Hy­po­glycemic episodes and risk of de­men­tia in older pa­tients with type 2 di­a­betes mel­li­tus. JAMA 2009;301:1565–1572
  39. Pun­tha­kee Z, Miller ME, Launer LJ, et al.; AC­CORD Group of In­ves­tigators; AC­CORD-‍MIND In­ves­tigators. Poor cog­ni­tive func­tion and risk of se­vere hy­po­glycemia in type 2 di­a­betes: post hoc epi­demi­o­log­ic anal­y­sis of the AC­CORD trial. Di­a­betes Care 2012;35:787–793
  40. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediter­ranean diet and mild cog­ni­tive im­pair­ment. Arch Neu­rol 2009;66:216–225
  41. Ooi CP, Loke SC, Yassin Z, Hamid T-A. Car­bo­hy­drates for im­prov­ing the cog­ni­tive per­for­mance of in­de­pen­dent-‍liv­ing older adults with nor­mal cog­ni­tion or mild cog­ni­tive im­pair­ment. Cochrane Database Syst Rev 2011;4:CD007220
  42. Richard­son K, Schoen M, French B, et al. Statins and cog­ni­tive func­tion: a sys­tematic re­view. Ann In­tern Med 2013;159:688–697
  43. El-‍Serag HB, Tran T, Ev­er­hart JE. Di­a­betes in­creases the risk of chron­ic liver dis­ease and hep­a­to­cel­lu­lar car­ci­no­ma. Gas­troen­terol­o­gy 2004;126:460–468

    43a. Cha­lasani N, Younos­si Z, Lavine JE, et al. The di­ag­no­sis and man­age­ment of non­al­co­holic fatty liver dis­ease: prac­tice guid­ance from the Amer­i­can As­so­ci­a­tion for the Study of Liver Dis­eases. Hep­a­tol­o­gy 2018;67:328–357

  44. Amer­i­can Gas­troen­tero­log­i­cal As­so­ci­a­tion. Amer­i­can Gas­troen­tero­log­i­cal As­so­ci­a­tion med­i­cal po­si­tion state­ment: non­al­co­holic fatty liver dis­ease. Gas­troen­terol­o­gy 2002;123:1702– 1704
  45. Cusi K, Orsak B, Bril F, et al. Long-‍term pi­ogli­ta­zone treat­ment for pa­tients with non­al­co­holic steatohep­ati­tis and predi­a­betes or type 2 di­a­betes mel­li­tus: a ran­dom­ized trial. Ann In­tern Med 2016;165:305–315
  46. Belfort R, Har­ri­son SA, Brown K, et al. A place­bo-‍con­trolled trial of pi­ogli­ta­zone in sub­jects with non­al­co­holic steatohep­ati­tis. N Engl J Med 2006;355:2297–2307
  47. Sanyal AJ, Cha­lasani N, Kowd­ley KV, et al.; NASH CRN. Pi­ogli­ta­zone, vi­ta­min E, or place­bo for non­al­co­holic steatohep­ati­tis. N Engl J Med 2010;362:1675–1685
  48. Arm­strong MJ, Gaunt P, Aithal GP, et al.; LEAN Trial Team. Li­raglu­tide safe­ty and efficacy in pa­tients with non-‍al­co­holic steatohep­ati­tis (LEAN): a mul­ti­cen­tre, dou­ble-‍blind, ran­domised, place­bo-‍con­trolled phase 2 study. Lancet 2016; 387:679–690
  49. Shimizu M, Suzu­ki K, Kato K, et al. Eval­u­a­tion of the ef­fects of da­pagliflozin, a sodi­um-‍glu­cose co-‍trans­porter-‍2 in­hibitor, on hep­at­ic steato­sis and fibro­sis using tran­sient elas­tog­ra­phy in pa­tients with type 2 di­a­betes and non-‍al­co­holic fatty liver dis­ease. Di­a­betes Obes Metab. 3 Septem­ber 2018 [Epub ahead of print]. DOI: 10.1111/ dom.13520
  50. Sat­tar N, Fitch­ett D, Hantel S, George JT, Zin­man B. Em­pagliflozin is as­so­ci­at­ed with im­provements in liver en­zymes po­ten­tially con­sis­tent with re­duc­tions in liver fat: re­sults from ran­domised tri­als in­clud­ing the EMPA-‍REG OUT­COME trial. Di­a­betolo­gia 2018;61:2155–2163
  51. Hardt PD, Bren­del MD, Kloer HU, Bret­zel RG. Is pan­cre­at­ic di­a­betes (type 3c di­a­betes) un­der­diag­nosed and mis­di­ag­nosed? Di­a­betes Care 2008;31(Suppl. 2):S165–S169
  52. Lee Y-K, Huang M-Y, Hsu C-Y, Su Y-C. Bidi­rec­tion­al re­la­tion­ship be­tween di­a­betes and acute pan­cre­ati­tis: a pop­u­la­tion-‍based co­hort study in Tai­wan. Medicine (Bal­ti­more) 2016;95: e2448
  53. Das SLM, Singh PP, Phillips ARJ, Mur­phy R, Wind­sor JA, Petrov MS. Newly di­ag­nosed di­a­betes mel­li­tus after acute pan­cre­ati­tis: a sys­tematic re­view and meta-‍anal­y­sis. Gut 2014;63: 818–831
  54. Petrov MS. Di­a­betes of the ex­ocrine pan­creas: Amer­i­can Di­a­betes As­so­ci­a­tion-compliant lex­i­con. Pan­cre­atol­o­gy 2017;17:523–526
  55. Thom­sen RW, Ped­er­sen L, Møller N, Kahlert J, Beck-‍Nielsen H, Sørensen HT. In­cretin-‍based ther­a­py and risk of acute pan­cre­ati­tis: a na­tion­wide pop­u­la­tion-‍based case-‍con­trol study. Di­a­betes Care 2015;38:1089–1098
  56. Tka´cˇ I, Raz I. Com­bined anal­y­sis of three large in­ter­ven­tional tri­als with gliptins in­di­cates in­creased in­ci­dence of acute pan­cre­ati­tis in pa­tients with type 2 di­a­betes. Di­a­betes Care 2017;40:284–286
  57. Bellin MD, Gel­rud A, Arreaza-‍Rubin G, et al. Total pan­cre­a­te­c­to­my with islet au­to­trans­plan­ta­tion: sum­ma­ry of an NIDDK work­shop. Ann Surg 2015;261:21–29
  58. Suther­land DER, Ra­do­se­vich DM, Bellin MD, et al. Total pan­cre­a­te­c­to­my and islet au­to­trans­plan­ta­tion for chron­ic pan­cre­ati­tis. J Am Coll Surg 2012;214:409–424; dis­cus­sion 424–426
  59. Quar­tuc­cio M, Hall E, Singh V, et al. Glycemic pre­dic­tors of in­sulin in­de­pen­dence after total pan­cre­a­te­c­to­my with islet au­to­trans­plan­ta­tion. J Clin En­docrinol Metab 2017;102:801–809
  60. Webb MA, Il­louz SC, Pol­lard CA, et al. Islet auto trans­plan­ta­tion fol­low­ing total pan­cre­a­te­c­to­my: a long-‍term as­sessment of graft func­tion. Pan­creas 2008;37:282–287
  61. Wu Q, Zhang M, Qin Y, et al. Sys­tematic re­view and meta-‍anal­y­sis of islet au­to­trans­plan­ta­tion after total pan­cre­a­te­c­to­my in chron­ic pan­cre­ati­tis pa­tients. En­docr J 2015;62:227–234
  62. Janghor­bani M, Van Dam RM, Wil­lett WC, Hu FB. Sys­tematic re­view of type 1 and type 2 di­a­betes mel­li­tus and risk of frac­ture. Am J Epi­demi­ol 2007;166:495–505
  63. Vester­gaard P. Dis­crep­an­cies in bone min­er­al den­si­ty and frac­ture risk in pa­tients with type 1 and type 2 di­a­betesda meta-‍anal­y­sis. Os­teo­poros Int 2007;18:427–444
  64. Schwartz AV, Vit­tinghoff E, Bauer DC, et al.; Study of Os­teo­porot­ic Frac­tures (SOF) Re­search Group; Os­teo­porot­ic Frac­tures in Men (MrOS) Re­search Group; Health, Aging, and Body Compo­si­tion (Health ABC) Re­search Group. As­so­ci­a­tion of BMD and FRAX score with risk of frac­ture in older adults with type 2 di­a­betes. JAMA 2011;305:2184–2192
  65. Kahn SE, Zin­man B, Lachin JM, et al.; A Di­a­betes Out­come Pro­gres­sion Trial (ADOPT) Study Group. Rosiglitazone-as­so­ci­at­ed frac­tures in type 2 di­a­betes: an anal­y­sis from A Di­a­betes Out­come Pro­gres­sion Trial (ADOPT). Di­a­betes Care 2008;31:845–851
  66. Tay­lor SI, Blau JE, Rother KI. Pos­si­ble ad­verse ef­fects of SGLT2 in­hibitors on bone. Lancet Di­a­betes En­docrinol 2015;3:8–10
  67. Bain­bridge KE, Hoff­man HJ, Cowie CC. Di­a­betes and hear­ing im­pair­ment in the Unit­ed States: au­dio­met­ric ev­i­dence from the Na­tion­al Health and Nu­tri­tion Ex­am­i­na­tion Sur­vey, 1999 to 2004. Ann In­tern Med 2008;149:1–10
  68. Mon­roe AK, Gles­by MJ, Brown TT. Di­ag­nos­ing and man­ag­ing di­a­betes in HIV-‍in­fect­ed pa­tients: cur­rent con­cepts. Clin In­fect Dis 2015; 60:453–462
  69. Scham­be­lan M, Ben­son CA, Carr A, et al.; In­ternational AIDS So­ci­ety-‍USA. Man­age­ment of metabol­ic com­pli­ca­tions as­so­ci­at­ed with an­tiretro­vi­ral ther­a­py for HIV-1 in­fec­tion: rec­om­men­da­tions of an In­ternational AIDS So­ci­ety-‍USA panel. J Ac­quir Im­mune Defic Syndr 2002; 31:257–275
  70. Kim PS, Woods C, Geor­goff P, et al. A1C un­der­es­ti­mates glycemia in HIV in­fec­tion. Di­a­betes Care 2009;32:1591–1593
  71. Wohl DA, Mc­Com­sey G, Tebas P, et al. Cur­rent con­cepts in the di­ag­no­sis and man­age­ment of metabol­ic com­pli­ca­tions of HIV in­fec­tion and its ther­a­py. Clin In­fect Dis 2006;43:645–653
  72. Dhind­sa S, Miller MG, McWhirter CL, et al. Testos­terone_ con­cen­tra­tions in di­a­bet­ic and nondi­a­bet­ic obese men. Di­a­betes Care 2010; 33:1186–1192
  73. Gross­mann M. Low testos­terone in men with type 2 di­a­betes: significance and treat­ment. J Clin En­docrinol Metab 2011;96:2341–2353
  74. Bhasin S, Cun­ning­ham GR, Hayes FJ, et al.; En­docrine So­ci­ety Task Force. Testos­terone_ ther­a­py in men with an­dro­gen deficien­cy syn­dromes: an En­docrine So­ci­ety clin­i­cal prac­tice guide­line. J Clin En­docrinol Metab 2010;95:2536–2559
  75. Li C, Ford ES, Zhao G, Croft JB, Bal­luz LS, Mok­dad AH. Preva­lence of self-re­ported clin­i­cally di­ag­nosed sleep apnea ac­cord­ing to obe­si­ty sta­tus in men and women: Na­tion­al Health and Nu­tri­tion Ex­am­i­na­tion Sur­vey, 2005–2006. Prev Med 2010;51:18–23
  76. West SD, Nicoll DJ, Stradling JR. Preva­lence of ob­struc­tive sleep ap­noea in men with type 2 di­a­betes. Tho­rax 2006;61:945–950
  77. Resnick HE, Red­line S, Sha­har E, et al.; Sleep Heart Health Study. Di­a­betes and sleep dis­tur­bances: find­ings from the Sleep Heart Health Study. Di­a­betes Care 2003;26:702–709
  78. Fos­ter GD, Sanders MH, Mill­man R, et al.; Sleep AHEAD Re­search Group. Ob­struc­tive sleep apnea among obese pa­tients with type 2 di­a­betes. Di­a­betes Care 2009;32:1017–1019
  79. Bibbins-‍Domingo K, Gross­man DC, Curry SJ, et al.; US Pre­ven­tive Ser­vices Task Force. Screen­ing for ob­struc­tive sleep apnea in adults: US Pre­ven­tive Ser­vices Task Force rec­om­men­da­tion state­ment. JAMA 2017;317:407–414
  80. Shaw JE, Pun­jabi NM, Wild­ing JP, Al­ber­ti KGMM, Zim­met PZ; In­ternational Di­a­betes Fed­er­a­tion Task­force on Epi­demi­ology and Pre­ven­tion. Sleep-‍dis­or­dered breath­ing and type 2 di­a­betes: a re­port from the In­ternational Di­a­betes Fed­er­a­tion Task­force on Epi­demi­ology and Pre­ven­tion. Di­a­betes Res Clin Pract 2008;81:2–12
  81. Khad­er YS, Dauod AS, El-‍Qaderi SS, Alka­fa­jei A, Batay­ha WQ. Pe­ri­odon­tal sta­tus of di­a­bet­ics com­pared with nondi­a­bet­ics: a meta-‍anal­y­sis. J Di­a­betes Com­pli­ca­tions 2006;20:59–68
  82. Casano­va L, Hugh­es FJ, Pre­shaw PM. Di­a­betes and pe­ri­odon­tal dis­ease: a two-‍way re­la­tion­ship. Br Dent J 2014;217:433–437
  83. de Groot M, Gold­en SH, Wag­n­er J. Psy­chological con­di­tions in adults with di­a­betes. Am Psy­chol 2016;71:552–562
  84. Young-‍Hyman D, de Groot M, Hill-‍Brig­gs F, Gon­za­lez JS, Hood K, Pey­rot M. Psychoso­cial care for peo­ple with di­a­betes: a po­si­tion state­ment of the Amer­i­can Di­a­betes As­so­ci­a­tion. Di­a­betes Care 2016;39:2126–2140
  85. Smith KJ, Be´land M, Clyde M, et al. As­so­ci­a­tion of di­a­betes with anx­i­ety: a sys­tematic re­view and meta-‍anal­y­sis. J Psy­cho­som Res 2013; 74:89–99
  86. Li C, Bark­er L, Ford ES, Zhang X, Strine TW, Mok­dad AH. Di­a­betes and anx­i­ety in US adults: find­ings from the 2006 Be­hav­ioral Risk Fac­tor Surveil­lance Sys­tem. Di­a­bet Med 2008;25:878–881
  87. Cox DJ, Irvine A, Gonder-‍Fred­er­ick L, Nowacek G, But­terfield J. Fear of hy­po­glycemia: quan­tification, val­i­da­tion, and uti­liza­tion. Di­a­betes Care 1987;10:617–621
  88. Wild D, von Maltzahn R, Bro­han E, Chris­tensen T, Clau­son P, Gonder-‍Fred­er­ick L. A crit­i­cal re­view of the lit­er­a­ture on fear of hy­po­glycemia in di­a­betes: im­pli­ca­tions for di­a­betes man­age­ment and pa­tient ed­u­ca­tion. Pa­tient Educ Couns 2007;68:10–15
  89. Zam­ban­i­ni A, New­son RB, Maisey M, Feher MD. In­jec­tion re­lat­ed anx­i­ety in in­sulin-‍treat­ed di­a­betes. Di­a­betes Res Clin Pract 1999;46:239–246
  90. Young-‍Hyman D, Pey­rot M. Psychoso­cial Care for Peo­ple with Di­a­betes. Alexan­dria, VA, Amer­i­can Di­a­betes As­so­ci­a­tion, 2012
  91. Amer­i­can Psy­chi­atric As­so­ci­a­tion. Di­ag­nos­tic and Sta­tis­ti­cal Man­u­al of Men­tal Disor­ders, Fifth Edi­tion [In­ternet], 2013. Avail­able from http:/‍/‍psychiatryonline.org/‍doi/‍book/‍10.1176/ appi.books.9780890425596. Ac­cessed 9 Novem­ber 2018
  92. Mit­so­nis C, Di­mopou­los N, Psar­ra V. P01-138 Clin­ical im­pli­ca­tions of anx­i­ety in di­a­betes: a crit­i­cal re­view of the ev­i­dence base (ab­stract). Eur Psy­chi­a­try 2009;24(Suppl. 1):S526
  93. Yeoh E, Choud­hary P, Nwoko­lo M, Ayis S, Amiel SA. In­ter­ven­tions that re­store aware­ness of hy­po­glycemia in adults with type 1 di­a­betes: a sys­tematic re­view and meta-‍anal­y­sis. Di­a­betes Care 2015;38:1592–1609
  94. Cox DJ, Gonder-‍Fred­er­ick L, Polon­sky W, Schlundt D, Ko­vatchev B, Clarke W. Blood glu­cose aware­ness train­ing (BGAT-2): long-‍term benefits. Di­a­betes Care 2001;24:637–642
  95. Gonder-‍Fred­er­ick LA, Schmidt KM, Vajda KA, et al. Psy­cho­me­t­ric prop­er­ties of the hy­po­glycemia fear sur­vey-‍II for adults with type 1 di­a­betes. Di­a­betes Care 2011;34:801–806
  96. Lust­man PJ, Griffith LS, Clouse RE. De­pres­sion in adults with di­a­betes. Re­sults of 5-yr fol­low-‍up study. Di­a­betes Care 1988;11:605– 612
  97. de Groot M, Crick KA, Long M, Saha C, Shubrook JH. Life­time du­ra­tion of de­pres­sive disor­ders in pa­tients with type 2 di­a­betes. Di­a­betes Care 2016;39:2174–2181
  98. Rubin RR, Ma Y, Mar­rero DG, et al.; Di­a­betes Pre­ven­tion Pro­gram Re­search Group. El­e­vat­ed de­pres­sion symp­toms, an­tide­pres­sant medicine use, and risk of de­vel­oping di­a­betes dur­ing the Di­a­betes Pre­ven­tion Pro­gram. Di­a­betes Care 2008;31:420–426
  99. An­der­son RJ, Freed­land KE, Clouse RE, Lust­man PJ. The preva­lence of co­mor­bid de­pres­sion in adults with di­a­betes: a meta-‍anal­y­sis. Di­a­betes Care 2001;24:1069–1078
  100. Clouse RE, Lust­man PJ, Freed­land KE, Griffith LS, McGill JB, Car­ney RM. De­pres­sion and coro­nary heart dis­ease in women with di­a­betes. Psy­cho­som Med 2003;65:376–383
  101. Katon WJ, Lin EHB, Von Korff M, et al. Col­lab­o­ra­tive care for pa­tients with de­pres­sion and chron­ic ill­nesses. N Engl J Med 2010;363: 2611–2620
  102. Pinhas-‍Hamiel O, Hamiel U, Levy-‍Shraga Y. Eat­ing disor­ders in ado­les­cents with type 1 di­a­betes: chal­lenges in di­ag­no­sis and treat­ment. World J Di­a­betes 2015;6:517–526
  103. Pa­pel­baum M, Ap­poli­na´rio JC, Mor­eira RdeO, Ellinger VCM, Kupfer R, Coutin­ho WF. Preva­lence of eat­ing disor­ders and psy­chi­atric co­mor­bidity in a clin­i­cal sam­ple of type 2 di­a­betes mel­li­tus pa­tients. Rev Bras Psiquia­tr 2005;27:135–138
  104. Young-‍Hyman DL, Davis CL. Dis­or­dered eat­ing be­hav­ior in in­di­vid­u­als with di­a­betes: im­por­tance of con­text, eval­u­a­tion, and clas­sification. Di­a­betes Care 2010;33:683–689
  105. Pinhas-‍Hamiel O, Hamiel U, Greenfield Y, et al. De­tect­ing in­ten­tion­al in­sulin omis­sion for weight loss in girls with type 1 di­a­betes mel­li­tus. Int J Eat Dis­ord 2013;46:819–825
  106. Goebel-‍Fabbri AE, Fikkan J, Franko DL, Pear­son K, An­der­son BJ, Weinger K. In­sulin re­stric­tion and as­so­ci­at­ed mor­bid­i­ty and mor­tal­i­ty in women with type 1 di­a­betes. Di­a­betes Care 2008;31:415–419
  107. Weinger K, Be­ver­ly EA. Bar­ri­ers to achiev­ing glycemic tar­gets: who omits in­sulin and why? Di­a­betes Care 2010;33:450–452
  108. Hud­son JI, Hiripi E, Pope HG Jr, Kessler RC. The preva­lence and cor­re­lates of eat­ing disor­ders in the Na­tion­al Comor­bid­i­ty Sur­vey Repli­ca­tion. Biol Psy­chi­a­try 2007;61:348–358
  109. Martyn-‍Nemeth P, Quinn L, Hack­er E, Park H, Ku­jath AS. Di­a­betes dis­tress may ad­versely af­fect the eat­ing styles of women with type 1 di­a­betes. Acta Di­a­betol 2014;51:683–686
  110. Pe­ter­son CM, Fis­ch­er S, Young-‍Hyman D. Top­i­cal re­view: a com­pre­hen­sive risk model for dis­or­dered eat­ing in youth with type 1 di­a­betes. J Pe­di­atr Psy­chol 2015;40:385–390
  111. Gar­ber AJ. Novel GLP-1 re­cep­tor ag­o­nists for di­a­betes. Ex­pert Opin In­ves­tig Drugs 2012; 21:45–57
  112. Su­visaari J, Pera¨la¨ J, Saarni SI, et al. Type 2 di­a­betes among per­sons with schizophre­nia and other psy­chot­ic disor­ders in a gen­er­al pop­u­la­tion sur­vey. Eur Arch Psy­chi­a­try Clin Neu­rosci 2008;258:129–136
  113. Koro CE, Fed­der DO, L’Ital­ien GJ, et al. As­sess­ment of in­de­pen­dent ef­fect of olan­za­p­ine and risperi­done on risk of di­a­betes among pa­tients with schizophre­nia: pop­u­la­tion based nest­ed case-‍con­trol study. BMJ 2002;325:243
  114. Lip­s­ka KJ, Ross JS, Wang Y, et al. Na­tion­al trends in US hos­pi­tal ad­mis­sions for hy­per­glycemia and hy­po­glycemia among Medi­care beneficia­ries, 1999 to 2011. JAMA In­tern Med 2014; 174:1116–1124
  115. Shorr RI, Ray WA, Daugh­er­ty JR, Griffin MR. In­ci­dence and risk fac­tors for se­ri­ous hy­po­glycemia in older per­sons using in­sulin or sul­fony­lureas. Arch In­tern Med 1997;157:1681–1686
  116. Ab­del­hafiz AH, Rodr´ıguez-‍Man~as L, Mor­ley JE, Sin­clair AJ. Hy­po­glycemia in older peo­ple - a less well rec­og­nized risk fac­tor for frailty. Aging Dis 2015;6:156–167
  117. Yun J-S, Ko S-H, Ko S-H, et al. Pres­ence of macroal­bu­min­uria pre­dicts se­vere hy­po­glycemia in pa­tients with type 2 di­a­betes: a 10-year fol­low-‍up study. Di­a­betes Care 2013;36:1283– 1289
  118. Chel­li­ah A, Burge MR. Hy­po­gly­caemia in el­der­ly pa­tients with di­a­betes mel­li­tus: caus­es and strate­gies for pre­vention. Drugs Aging 2004; 21:511–530
  119. Davies MJ, D’Alessio DA, Frad­kin J, et al. Man­age­ment of hy­per­glycemia in type 2 di­a­betes, 2018. A con­sen­sus re­port by the Amer­i­can Di­a­betes As­so­ci­a­tion (ADA) and the Eu­ro­pean As­so­ci­a­tion for the Study of Di­a­betes (EASD). Di­a­betes Care 2018;41:2669–2701